Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663930 | 0.82 | ALDH1A1 (0.46) | ALOX15LMNAALDH1A1FAAHCNR1 | |
| SCHEMBL11318774 | 0.80 | — | — | |
| SCHEMBL7016617 | 0.80 | — | — | |
| SCHEMBL10904686 | 0.79 | TRPA1 (0.31) | ALDH1A1TRPA1 | |
| SCHEMBL3145515 | 0.77 | — | — | |
| SCHEMBL5450476 | 0.77 | — | — | |
| SCHEMBL9698326 | 0.76 | MEN1 (0.33) | MEN1CYP2C19RECQLKMT2ALMNA | |
| SCHEMBL17025710 | 0.75 | MEN1 (0.38) | MEN1CYP2C19RECQLKMT2AALOX15 | |
| SCHEMBL685676 | 0.75 | MEN1 (0.38) | MEN1CYP2C19RECQLKMT2AALOX15 | |
| SCHEMBL2170363 | 0.75 | CYP2C19 (0.38) | MEN1CYP2C19RECQLKMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-114380861-B | Preparation method of fosinopril sodium intermediate | 浙江华海药业股份有限公司 | 2026-05-08 | — | — | CN | disclosed |
| WO-2024182772-A2 | MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-114890994-B | Histamine receptor antagonist and preparation thereof | 成都施贝康生物医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-114890994-A | Histamine receptor antagonist and preparation thereof | 成都施贝康生物医药科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114380861-A | Preparation method of fosinopril sodium intermediate | 浙江华海药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114380861-A | Preparation method of fosinopril sodium intermediate | 浙江华海药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4A11, CYP4F11 | MEN1 4555/4885CYP2C19 72/4885RECQL 3265/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | MEN1 3214/4885CYP2C19 4780/4885RECQL 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.